Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • davidmilldou davidmilldou Feb 3, 2014 11:56 AM Flag

    going to zero as cudc-427 kills people

     

    end of story

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think longs should try contacting the management or investor relations ASAP and see what they have to say. Until then we cannot simply call this david guy a fraud can we.

    • Seriously, get a life.

    • shorts are welcome to post opinions but you are also requested to substantiate whatever you post here. just saying "kills people" "going to zero" means nothing to any of us. Provide analysis of what you believe and then expect us to start a discussion. You might be right but "guess work" is as good as tossing/casinos, right?? So in your next post please put out what all you think are the arguments against cris for now. We all know about the cudc-427 and we also know a lot more than that. Ok? so expecting a better post from you soon. Doesn't matter if it is bashing but something intelligent.

    • I had the same impression about Dan. Even his transaction history does not reveal any buying activity. Nothing we can do about it anyway. Often investors are stuck with poor performing CEOs.

    • Thanks. I took this as a "buy opportunity" and loaded up 10K more shares. Time to shake the money tree.

    • Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427

      Email
      Printer
      Friendly
      Share:

      facebook ↓ More
      smaller Text larger

      Curis Announces Removal of FDA Partial Clinical Hold on CUDC-427

      - Curis Expects to Reinitiate Enrollment in Single Agent Phase 1 Study of CUDC-427 in Patients With Solid Tumors or Lymphoma -

      LEXINGTON, Mass., March 31, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its complete response submission to the November 2013 partial clinical hold on CUDC-427 has been reviewed and that the FDA has determined that it is safe to proceed under the IND. The FDA also indicated that detailed official correspondence regarding the determination will be released in the near future. Curis will provide additional details, if applicable, based upon further communications from the FDA as they become available.

      "We have worked diligently with the FDA and anticipate re-opening the monotherapy Phase 1 study as soon as possible," said Ali Fattaey, Ph.D., President and Chief Operating Officer of Curis. "We continue to believe that CUDC-427 has significant potential as an anti-cancer agent and expect to proceed with CUDC-427's overall development plan, including our planned study to investigate CUDC-427 in combination with capecitabine in HER-2 negative advanced breast cancer patients

    • mrbigs@cox.net mrbigs Apr 27, 2014 10:01 PM Flag

      Paid manipulator.

 
CRIS
1.85-0.07(-3.65%)May 4 4:00 PMEDT